These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35780109)

  • 21. Substance use policy and practice in the COVID-19 pandemic: Learning from early pandemic responses through internationally comparative field data.
    Aronowitz SV; Carroll JJ; Hansen H; Jauffret-Roustide M; Parker CM; Suhail-Sindhu S; Albizu-Garcia C; Alegria M; Arrendondo J; Baldacchino A; Bluthenthal R; Bourgois P; Burraway J; Chen JS; Ekhtiari H; Elkhoy H; Farhoudian A; Friedman J; Jordan A; Kato L; Knight K; Martinez C; McNeil R; Murray H; Namirembe S; Radfar R; Roe L; Sarang A; Scherz C; Tay Wee Teck J; Textor L; Thi Hai Oanh K
    Glob Public Health; 2022 Dec; 17(12):3654-3669. PubMed ID: 36692903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A rapid review of the impacts of "Big Events " on risks, harms, and service delivery among people who use drugs: Implications for responding to COVID-19.
    Zolopa C; Hoj S; Bruneau J; Meeson JS; Minoyan N; Raynault MF; Makarenko I; Larney S
    Int J Drug Policy; 2021 Jun; 92():103127. PubMed ID: 33549464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health service utilisation and access for people who inject drugs during COVID-19.
    Efunnuga H; Higgs P; Walker S; O'Keefe D
    Drug Alcohol Rev; 2022 Sep; 41(6):1304-1310. PubMed ID: 35266229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 'More of the same, but worse than before': A qualitative study of the challenges encountered by people who use drugs in Nova Scotia, Canada during COVID-19.
    Comeau E; Bonn M; Wildeman S; Herder M
    PLoS One; 2023; 18(4):e0283979. PubMed ID: 37018353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. "They have more than enough to do than patch up people like me." Experiences of seeking support for self-harm in lockdown during the COVID-19 pandemic.
    Sass C; Farley K; Brennan C
    J Psychiatr Ment Health Nurs; 2022 Aug; 29(4):544-554. PubMed ID: 35403770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of COVID-19 on substance use disorder treatment services in Kenya: Qualitative findings from healthcare providers.
    Muller A; Akiyama MJ; Riback L; Nyakowa M; Musyoki H; Cherutich P; Kurth A
    Int J Drug Policy; 2022 Jul; 105():103710. PubMed ID: 35580533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Responding to a surge in overdose deaths: perspectives from US syringe services programs.
    Frost MC; Austin EJ; Corcorran MA; Briggs ES; Behrends CN; Juarez AM; Frank ND; Healy E; Prohaska SM; LaKosky PA; Kapadia SN; Perlman DC; Schackman BR; Des Jarlais DC; Williams EC; Glick SN
    Harm Reduct J; 2022 Jul; 19(1):79. PubMed ID: 35854351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Bronze Age of drug checking: barriers and facilitators to implementing advanced drug checking amidst police violence and COVID-19.
    Carroll JJ; Mackin S; Schmidt C; McKenzie M; Green TC
    Harm Reduct J; 2022 Feb; 19(1):9. PubMed ID: 35120531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. "It's an emotional roller coaster… But sometimes it's fucking awesome": Meaning and motivation of work for peers in overdose response environments in British Columbia.
    Pauly BB; Mamdani Z; Mesley L; McKenzie S; Cameron F; Edwards D; Howell A; Knott M; Scott T; Seguin R; Greer AM; Buxton JA
    Int J Drug Policy; 2021 Feb; 88():103015. PubMed ID: 33176249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Motivations for concurrent use of uppers and downers among people who access harm reduction services in British Columbia, Canada: findings from the 2019 Harm Reduction Client Survey.
    Steinberg A; Mehta A; Papamihali K; Lukac CD; Young S; Graham B; Lock K; Fleury M; Buxton JA
    BMJ Open; 2022 May; 12(5):e060447. PubMed ID: 35501101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Program Adaptations to Provide Harm Reduction Services During the COVID-19 Pandemic: A Qualitative Study of Syringe Services Programs in the U.S.
    Frost MC; Sweek EW; Austin EJ; Corcorran MA; Juarez AM; Frank ND; Prohaska SM; LaKosky PA; Asher AK; Broz D; Jarlais DCD; Williams EC; Glick SN
    AIDS Behav; 2022 Jan; 26(1):57-68. PubMed ID: 34110506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ethical by Design: Engaging the Community to Co-design a Digital Health Ecosystem to Improve Overdose Prevention Efforts Among Highly Vulnerable People Who Use Drugs.
    Claborn KR; Creech S; Whittfield Q; Parra-Cardona R; Daugherty A; Benzer J
    Front Digit Health; 2022; 4():880849. PubMed ID: 35712228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Having a voice and saving lives: a qualitative survey on employment impacts of people with lived experience of drug use working in harm reduction.
    ; Austin T; Boyd J
    Harm Reduct J; 2021 Jan; 18(1):1. PubMed ID: 33407500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of the COVID-19 pandemic on access to supervised consumption programs.
    Gubskaya E; Kennedy MC; Hayashi K; Cui Z; Milloy MJ; Kerr T
    Subst Abuse Treat Prev Policy; 2023 Mar; 18(1):16. PubMed ID: 36899417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Descriptive Comparison of Substance Use Services in Recovery and Isolation Sites for People Experiencing Homelessness During the COVID-19 Pandemic, Boston and Toronto.
    Harris MTH; Young S; Barocas J; Bayoumi AM; Caudarella A; Laurence G; Tomanovich M; Komaromy M
    Public Health Rep; 2021; 136(5):532-537. PubMed ID: 34269625
    [No Abstract]   [Full Text] [Related]  

  • 36. Harm Reduction for Adolescents and Young Adults During the COVID-19 Pandemic: A Case Study of Community Care in Reach.
    Noyes E; Yeo E; Yerton M; Plakas I; Keyes S; Obando A; Gaeta JM; Taveras EM; Chatterjee A
    Public Health Rep; 2021 May; 136(3):301-308. PubMed ID: 33673755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The changing landscape of pharmaceutical alternatives to the unregulated drug supply during COVID-19.
    McCrae K; Glegg S; Goyer MÉ; Le Foll B; Brar R; Sutherland C; Fairbairn N
    Harm Reduct J; 2022 Jul; 19(1):77. PubMed ID: 35836189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug use behaviors, trauma, and emotional affect following the overdose of a social network member: A qualitative investigation.
    Macmadu A; Frueh L; Collins AB; Newman R; Barnett NP; Rich JD; Clark MA; Marshall BDL
    Int J Drug Policy; 2022 Sep; 107():103792. PubMed ID: 35816791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hoots and harm reduction: a qualitative study identifying gaps in overdose prevention among women who smoke drugs.
    Bardwell G; Austin T; Maher L; Boyd J
    Harm Reduct J; 2021 Mar; 18(1):29. PubMed ID: 33678163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. "It's my frenemy": A qualitative exploration of knowledge and perceptions of fentanyl use during the COVID-19 pandemic in people who use drugs at a syringe services program in Philadelphia, PA.
    Bass SB; Kelly PJA; Pandit-Kerr S; Pilla J; Morris K; Larsen E; Wisdom JP; Torralva PR
    Front Public Health; 2022; 10():882421. PubMed ID: 35937263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.